Experimental ceramide therapy takes on tough leukemia
NCT ID NCT04716452
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new drug called C6 ceramide nanoliposome (Ceraxa) in 15 adults with acute myeloid leukemia that has come back or not responded to treatment. The drug is given by IV twice a week, and the main goal is to check safety and find the right dose. It is too early to know if it works, but researchers will also look for signs of remission.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- C6 ceramide nanoliposome (Ceraxa)
- What this could lead to
- If it works, this could point toward a new treatment option for people with hard-to-treat acute myeloid leukemia.
- What could go wrong
- This is a very early Phase 1 safety trial with only 15 people. It is too small to prove effectiveness, and the drug may not work or may cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA REFRACTORY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Virginia Cancer Center
RECRUITINGCharlottesville, Virginia, 22903, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered immune cells take aim at Hard-to-Treat leukemia
- New combo aims to beat High-Risk leukemia and MDS
- Experimental CAR-T therapy takes on tough leukemia
- Cord blood immune cells tested against tough leukemia
- New targeted therapy shows promise for Tough-to-Treat leukemia
- Experimental T-Cell combo targets Hard-to-Treat leukemia